Evidence map›Paper›PMID 32432360›Full record

ArticleClinical cardiology2020

Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective study.

Sangmee Sharon Bae, Buzand Oganesian, Ilana Golub, Christina Charles-Schoeman

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Idiopathic inflammatory myopathies.Nature reviews. Disease primers · 2021
    Review
  12. Idiopathic inflammatory myopathies.Nature reviews. Disease primers · 2021
    Article
  13. Review
  14. Observational
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sangmee Sharon BaeDivision of Rheumatology, University of California Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7216-7219
Buzand OganesianDivision of Rheumatology, University of California Los Angeles, Los Angeles, California, USA.
Ilana GolubDivision of Rheumatology, University of California Los Angeles, Los Angeles, California, USA.
Christina Charles-SchoemanDivision of Rheumatology, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · US

Funding

Mechanisms Linking Joint Inflammation and Atherosclerosis in Rheumatoid ArthritisR01HL123064 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2015 to 2019
$2.7M
HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid ArthritisK23HL094834 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHARLES-SCHOEMAN, CHRISTINA · 2009 to 2013
$693k
NHLBI NIH HHS 5K23HL094834NHLBI NIH HHS R01HL123064
6 · The paper itself

Abstract

backgroundStatins are the most widely used lipid lowering therapies which reduce cardiovascular risk, but are associated with muscular adverse events (AEs). Idiopathic inflammatory myopathies (IIM) are autoimmune diseases of the muscle with higher risk of cardiovascular disease. More data is needed regarding statin safety in patients with intrinsic muscle disease such as IIM. HYPOTHESIS: Statins are tolerated in patients with IIM without leading to significant increase in muscular AEs.

methodsStatin use was retrospectively examined in a longitudinal IIM cohort. Safety analysis included assessment of muscular and nonmuscular AEs by chart review. IIM patients receiving a statin during the cohort follow-up period were matched to IIM patients not receiving a statin for comparative analysis of longitudinal outcomes.

results33/214 patients had a history of statin use. 63% started for primary prevention, while others were started for clinical ASCVD events, vascular surgery, IIM related heart failure, and cardiac transplantation. A high intensity statin was used in nine patients with non-HMGCR myositis, and tolerated in 8/9 patients. Statin related muscular AE was noted in three patients. There were no cases of rhabdomyolysis, or statin related nonmuscular AEs in a median observation period of 5 years. In patients newly started on statins during cohort follow-up (n = 7) there was no change in disease activity after statin initiation. Long term outcomes were not different between statin and nonstatin IIM control groups.

conclusionStatins were well tolerated in patients with non-HMGCR positive IIM. Given the accelerated atherosclerotic risk in IIM patients, further prospective studies of statin safety in IIM patients are warranted.

Indexed as

AgedAtherosclerosisAutoantibodiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesMaleMiddle AgedMyositisRetrospective StudiesRisk FactorsTreatment OutcomeAutoantibodiesHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA Reductasesidiopathic inflammatory myopathymuscle adverse eventsretrospective studystatin use

Identifiers

PMID32432360
PMCPMC7368310
OpenAlexW3027287026

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.